Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4545199 | 0.72 | LMNA (0.49) | PKMALDH1A1 | |
| SCHEMBL14203242 | 0.67 | CREBBP (0.46) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL4548527 | 0.62 | LMNA (0.40) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL10201806 | 0.61 | CA5A (0.44) | PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL2796551 | 0.61 | LMNA (0.52) | PKMALDH1A1 | |
| SCHEMBL12253686 | 0.61 | PKM (0.57) | PKMALDH1A1 | |
| SCHEMBL1909365 | 0.61 | PKM (0.61) | PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL13199303 | 0.61 | TPMT (0.50) | PKMALDH1A1TSHR | |
| SCHEMBL96185 | 0.60 | CA5A (0.52) | SMN1; SMN2 | |
| SCHEMBL8675250 | 0.60 | KDM4E (0.49) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962600-B2 | Neuroprotective compounds and their use | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120108549-A1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108549-A1 | NEUROPROTECTIVE COMPOUNDS AND THEIR USE | NLN, ATP6V1B2, BDNF | PKM 2960/4885ALDH1A1 978/4885TSHR 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.